51 days ago
I have now written to both regulators demanding a full enquiry into Stuart Ashman and Skin biotherapeutics (SBTX) as , at the very least , they have broken AIM Rule 10 at worse they have done a placing at a false price because of non disclosure to the wider market of adverse trading performance. In the wake of December 5 prelims there now needs to be a full formal enquiry
